Key result
Carriers of the prothrombin or factor V gene mutation had a higher 10-year cumulative incidence of recurrent venous thromboembolism than non-carriers.
Why the study?
Does the presence of prothrombin or factor V gene mutations increase the risk of recurrent venous thromboembolic complications in outpatients with a first episode of deep-vein thrombosis?
Cohort (n=251)
Does the presence of prothrombin or factor V gene mutations increase the risk of recurrent venous thromboembolic complications in outpatients with a first episode of deep-vein thrombosis?
Carriers of prothrombin or factor V gene mutations have a significantly increased risk of recurrent venous thromboembolic complications after a first episode of deep-vein thrombosis.
Answers are grounded in this paper and cite their sources.
May support extended anticoagulation in carriers after first DVT; leaves open whether genotyping should guide duration in trials.
Carriers of a mutation in the prothrombin (clotting factor II) or factor V gene have a 2- to 4-fold greater risk for venous thromboembolism than subjects without the mutations. Whether both mutations also predispose to recurrent venous thromboembolism is unclear. Outpatients who had a first episode of proven symptomatic deep-vein thrombosis and a long-term follow-up were studied. The outcome measure was the cumulative incidence of confirmed venous thromboembolic complications. Two hundred fifty-one patients were enrolled in the study. Mean duration of follow-up was 8.3 years. The prothrombin gene mutation was demonstrated in 27 patients (prevalence, 10.8%; 95% CI, 6.9 to 14.6), and the factor V gene mutation was demonstrated in 41 patients (prevalence, 16.3%; 95% CI, 11.8 to 20.9). The cumulative incidence of venous thromboembolic complications after 10 years was 61.3% (95% CI, 35.7 to 87.9), and the hazard ratio was 2.4 (95% CI, 1.3 to 4.7; P =.004) in patients with the prothrombin gene mutation); the cumulative incidence of venous thromboembolic complications after 10 years was 55.2% (95% CI, 36.4 to 74.0), and the hazard ratio was 2.4 (95% CI, 1.4 to 4.1; P =.001) in patients with the factor V gene mutation. In comparison, the cumulative incidence of venous thromboembolic complications after 10 years was 23.1% (95% CI, 16.2 to 30.1) in patients without the mutations. Prothrombin and factor V gene mutations occur frequently in patients with venous thrombosis and are associated with an increased risk for recurrent venous thromboembolic complications.
No takes yet. Share an insight, caveat, or question.
Simioni et al. (2000) conducted a cohort in First episode of deep-vein thrombosis (n=251). Prothrombin or factor V gene mutation vs. Patients without the mutations was evaluated on Cumulative incidence of confirmed venous thromboembolic complications (HR 2.4, 95% CI 1.3 to 4.7, p=0.004). Carriers of the prothrombin or factor V gene mutation had a higher 10-year cumulative incidence of recurrent venous thromboembolism than non-carriers.
Synapse has enriched 10 related papers. Consider them for comparative context: